

(FILE 'HOME' ENTERED AT 13:07:47 ON 06 MAR 2001)

FILE 'CPLUS, USPATFULL' ENTERED AT 13:07:55 ON 06 MAR 2001

L1 0 S COMPETITIVE PROBE HYBRIDIZATION  
L2 1326 S COMPET? (P) PROBE (P)HYBRID?  
L3 274 S COMPET? (5A) PROBE (5A)HYBRID?  
L4 274 DUPLICATE REMOVE L3 (0 DUPLICATES REMOVED)  
L5 8 S L4 AND (OPTIMIZ? (P) TEMPERATURE)

L5 ANSWER 2 OF 8 USPATFULL

SUMM . . . exogenous DNA (e.g., DNA spilled onto lab surfaces) or cross-contamination is also a major consideration. Reaction conditions must be carefully **optimized** for each different primer pair and target sequence, and the process can take days, even for an experienced investigator. The. . . to penetrate the clinical market in a significant way. The same concerns arise with LCR, as LCR must also be **optimized** to use different oligonucleotide sequences for each target sequence. In addition, both methods require expensive equipment, capable of precise **temperature cycling**.

DETD . . . contains sequences at its 3' end which are substantially the same as sequences located at the 5' end of a **probe** oligonucleotide; these regions will **compete** for **hybridization** to the same segment along a complementary target nucleic acid.

DETD **Temperature** is also an important factor in the hybridization of oligonucleotides. The range of **temperature** tested will depend in large part, on the design of the oligonucleotides, as discussed above. In a preferred embodiment, the. . . a nucleic acid is only an approximation, the reaction temperatures chosen for initial tests should bracket the calculated T<sub>sub.m</sub>. While **optimizations** are not limited to this, 5.degree. C. increments are convenient test intervals in these **optimization** assays.

DETD . . . manufacturer's instructions are a resource for this information. When developing an assay utilizing any particular cleavage agent, the oligonucleotide and **temperature** **optimizations** described above should be performed in the buffer conditions best suited to that cleavage agent.

DETD . . . by the addition of 5 .mu.l of the appropriate enzyme mixture. The reaction mixtures were then incubated at 63.degree. C. **temperature** for 15 minutes. The reactions were stopped by the addition of 8 .mu.l of 95% formamide with 20 mM EDTA. . . nucleases tested have the ability to catalyze invader-directed cleavage in at least one of the buffer systems tested. Although not **optimized** here, these cleavage agents are suitable for use in the methods of the present invention.

=> d bib,ab 2

L5 ANSWER 2 OF 8 USPATFULL

AN 2000:91698 USPATFULL

TI Cleavage of nucleic acids

IN Prudent, James R., Madison, WI, United States

Hall, Jeff G., Madison, WI, United States

Lyamichev, Victor I., Madison, WI, United States

Brow, Mary Ann D., Madison, WI, United States

Dahlberg, James E., Madison, WI, United States

PA Third Wave Technologies, Inc., Madison, WI, United States (U.S. corporation)

PI US 6090543 20000718

AI US 1996-759038 19961202 (8)

RLI Continuation-in-part of Ser. No. US 1996-756386, filed on 26 Nov 1996 which is a continuation-in-part of Ser. No. US 1996-682853, filed on 12 Jul 1996 which is a continuation-in-part of Ser. No. US 1996-599491, filed on 24 Jan 1996 76 Ser. No. US 1996-758314, filed on 2 Dec 1996

DT Utility  
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Shoemaker, Debra  
LREP Medlen & Carroll, LLP  
CLMN Number of Claims: 27  
ECL Exemplary Claim: 1  
DRWN 102 Drawing Figure(s); 117 Drawing Page(s)  
LN.CNT 11426  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. The structure-specific nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.

L5 ANSWER 3 OF 8 USPATFULL  
AN 1999:163423 USPATFULL  
TI Detection of nucleic acid sequences by invader-directed cleavage  
IN Brow, Mary Ann D., Madison, WI, United States  
Hall, Jeff Steven Grotelueschen, Madison, WI, United States  
Lyamichev, Victor, Madison, WI, United States  
Olive, David Michael, Madison, WI, United States  
Prudent, James Robert, Madison, WI, United States  
PA Third Wave Technologies, Inc., CA, United States (U.S. corporation)  
PI US 6001567 19991214  
AI US 1996-682853 19960712 (8)  
RLI Continuation-in-part of Ser. No. US 1996-599491, filed on 24 Jan 1996,  
now patented, Pat. No. US 5846717  
DT Utility  
EXNAM Primary Examiner: Arthur, Lisa B.; Assistant Examiner: Souaya, Jehanne  
LREP Medlen & Carroll, LLP  
CLMN Number of Claims: 15  
ECL Exemplary Claim: 1  
DRWN 66 Drawing Figure(s); 82 Drawing Page(s)  
LN.CNT 7836  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention relates to means for the detection and  
characterization of nucleic acid sequences, as well as variations in  
nucleic acid sequences. The present invention also relates to methods  
for forming a nucleic acid cleavage structure on a target sequence and  
cleaving the nucleic acid cleavage structure in a site-specific manner.  
The 5' nuclease activity of a variety of enzymes is used to cleave the  
target-dependent cleavage structure, thereby indicating the presence of  
specific nucleic acid sequences or specific variations thereof. The  
present invention further relates to methods and devices for the  
separation of nucleic acid molecules based by charge.

L5 ANSWER 7 OF 8 USPATFULL  
AN 88:53750 USPATFULL  
TI Displacement polynucleotide assay employing polyether and diagnostic  
kit  
IN Williams, Jon I., Montclair, NJ, United States  
Ellwood, Marian S., Summit, NJ, United States  
Collins, Mary, Natick, MA, United States  
Fritsch, Edward F., Concord, MA, United States  
Brewen, Joseph G., Convent Station, NJ, United States  
Diamond, Steven E., Springfield, NJ, United States  
PA Allied Corporation, Morristown, NJ, United States (U.S. corporation)  
Genetics Institute, Inc., Cambridge, MA, United States (U.S.  
corporation)  
PI US 4766064 19880823  
AI US 1984-684308 19841220 (6)  
DCD 20010529  
RLI Continuation-in-part of Ser. No. US 1984-607885, filed on 7 May 1984  
DT Utility  
EXNAM Primary Examiner: Warren, Charles F.; Assistant Examiner: Jay, Jeremy  
M.  
LREP Doernberg, Alan M.  
CLMN Number of Claims: 31  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 3 Drawing Page(s)  
LN.CNT 1834  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A diagnostic reagent is disclosed containing a complex of a probe  
polynucleotide (P) bound via purine/pyrimidine hydrogen bonding to a  
labeled polynucleotide (L). The probe (P) contains a target binding  
region (TBR) capable of binding to a target nucleotide sequence (G) of  
a biological sample. A method is disclosed in which contact with a sample  
containing the target nucleotide sequence (G) causes binding, initially  
between G and a single-stranded portion (IBR) of the target binding  
region (TBR). Thereafter the labeled polynucleotide (L) is displaced  
from the complex by branch migration of (G) into the (P)/(L) binding  
region. A volume excluding polymeric agent such as poly(ethylene oxide)  
(PEO or PEG) or other polyethers enhances the rate of appearance of  
displaced labeled polynucleotide. Determination of displaced labeled  
polynucleotide (L) gives a value which is a function of the presence  
and concentration of target nucleotide sequence (G) in the sample.

L6 ANSWER 1 OF 1 USPATFULL  
AN 1998:22060 USPATFULL  
TI Amplification and detection of mycobacterial DNA K nucleic acids  
IN Nycz, Colleen Marie, Raleigh, NC, United States  
Nadeau, James G., Chapel Hill, NC, United States  
Scott, Patricia Brinkley, Apex, NC, United States  
Shank, Daryl Dee, BelAir, MD, United States  
Spears, Patricia Anne, Raleigh, NC, United States  
PA Becton, Dickinson and Company, Franklin Lakes, NJ, United States (U.S.  
corporation)  
PI US 5723296 19980303  
AI US 1996-644729 19960510 (8)  
RLI Continuation of Ser. No. US 1994-347551, filed on 30 Nov 1994, now  
abandoned  
DT Utility  
EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Fredman, Jeffrey  
LREP Fugit, Donna R.  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 1269  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Methods for identification or detection of a species of an organism or  
a  
group of related species of an organism by species non-specific  
amplification of a target sequence followed by species- or  
group-specific detection of the amplification products. Also provided  
are a target sequence which is amplifiable in multiple species of  
mycobacteria using a single pair of amplification primers and species-  
and group-specific detector probes for hybridization to the assay  
region of the amplified target. Blocking oligonucleotides are employed  
to allow discrimination among species in which the amplified target  
sequences are sufficiently similar that they cross-hybridize to an  
assay  
probe.

=> d kwic

L6 ANSWER 1 OF 1 USPATFULL  
DETD . . . temperatures resulted in equivalent or higher signal from M.  
avium and M. intracellulare, but also increased signal from M.  
chelonae.  
**Temperature optimization** for assay  
**hybridization** using the blocker **probe** SEQ ID NO: 11  
indicated that 42.5.degree. C. hybridization gave the best ratio of  
specific- to non-specific signal and provided >100 fold discrimination  
between signals from the specific and non-specific targets. Such  
hybridization **temperature** studies are routine for  
**optimizing hybridization** of a **probe** or  
primer to its target sequence and would usually be performed to  
optimize  
the performance of any blocking oligonucleotide.